News & Updates

Between 2015 and 2020, nearly a third of people living with HIV (PLHIV) in Asia-Pacific countries still show a detectable viral load, according to a study presented at the HIV Glasgow 2022 Congress.

The addition of vebicorvir to entecavir in treatment-naïve patients with chronic hepatitis B virus (HBV) infection provides further antiviral activity, with a positive safety and tolerability profile, results of a phase II trial have shown.

Patients with concomitant chronic kidney disease (CKD) and type 2 diabetes (T2D) who are undergoing mineralocorticoid receptor blockade with finerenone are better protected against pneumonia and COVID-19, according to a secondary analysis of data from the FIDELITY trials.

Cefmetazole and cefoxitin prove to be effective in the treatment of patients with urinary tract infections (UTIs) due to extended-spectrum beta-lactamase (ESBL)–producing Escherichia coli, according to two separate studies presented at IDWeek 2022.

While rare, infection with antibiotic-resistant gram-negative bacteria (AR-GNB) following a positive COVID-19 diagnosis is more severe and often results in worse outcomes, according to a study presented at the recent Virtual ID Week 2022.

Adults with a high baseline HIV-1 RNA or low CD4 count may benefit from initial treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), which has been shown to be safe and efficacious over 5 years of follow-up in a study presented at the ID Week 2022 Virtual Conference.

In patients with Clostridioides difficile infections (CDI), treatment with ridinilazole (RDZ) leads to high and sustained rates of clinical response, according to a study presented at the recently concluded Virtual ID Week 2022. Compared with vancomycin (VAN), RDZ also more strongly prevents recurrent CDI (rCDI).

Use of molnupiravir or nirmatrelvir/ritonavir in high-risk patients with mild-to-moderate COVID-19 is associated with reduced in-hospital mortality, reduced hospital admissions or readmissions, and potential healthcare cost savings, according to a real-world retrospective cohort study led by researchers from the Chinese University of Hong Kong and the University of Hong Kong.